XML 37 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Revision of Previously Issued Quarterly Financial Statements (Tables)
 12 Months Ended
Dec. 31, 2022
Prior Period Adjustment [Abstract]  
Schedule of error corrections and prior period adjustments The impact of the revision on the Company’s financial statements is reflected in the following table:
 
 
  
As previously

report
 
 
Adjustment
 
 
As revised
 
Balance Sheet for March 31, 2022 (unaudited)
  
 
 
Additional
paid-in
capital
  
$
434,305
 
 
$
797
 
 
$
435,102
 
Accumulated deficit
  
 
(429,179
) 
 
 
(797
) 
 
 
(429,976
) 
Consolidated Statement of Operations and Comprehensive Loss for the three months March 31, 2022 (unaudited)
  
 
 
Research and development expenses
  
 
4,240
 
 
 
241
 
 
 
4,481
 
Selling, general and administrative expenses
  
 
3,648
 
 
 
556
 
 
 
4,204
 
  
 
 
 
 
 
 
 
 
 
 
 
Total operating expenses
  
 
7,888
 
 
 
797
 
 
 
8,685
 
Operating loss
  
 
(7,543
) 
 
 
(797
) 
 
 
(8,340
) 
Net loss
  
 
(8,203
) 
 
 
(797
) 
 
 
(9,000
) 
Total other comprehensive loss
  
 
(8,201
) 
 
 
(797
) 
 
 
(8,998
) 
Basic and diluted loss per common share
  
 
(1.00
) 
 
 
(0.10
) 
 
 
(1.10
) 
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended March 31, 2022 (unaudited)
  
 
 
Compensation expense for issuance of stock options
  
 
1,474
 
 
 
797
 
 
 
2,271
 
Net loss
  
 
(8,203
) 
 
 
(797
) 
 
 
(9,000
) 
Consolidated Statement of Cash Flows for the three months ended March 31, 2022 (unaudited)
  
 
 
Net loss
  
 
(8,203
) 
 
 
(797
) 
 
 
(9,000
) 
Stock option compensation expense
  
 
1,474
 
 
 
797
 
 
 
2,271
 
Balance Sheet for June 30, 2022 (unaudited)
  
 
 
Additional
paid-in
capital
  
 
435,922
 
 
 
1,299
 
 
 
437,221
 
Accumulated deficit
  
 
(438,836
) 
 
 
(1,299
) 
 
 
(440,135
) 
 
 
 
 
  
As previously

report
 
 
Adjustment
 
 
As revised
 
Consolidated Statement of Operations and Comprehensive Loss for the three months June 30, 2022 (unaudited)
  
 
 
Research and development expenses
  
 
5,456
 
 
 
150
 
 
 
5,606
 
Selling, general and administrative expenses
  
 
4,145
 
 
 
352
 
 
 
4,497
 
  
 
 
 
 
 
 
 
 
 
 
 
Total operating expenses
  
 
9,601
 
 
 
502
 
 
 
10,103
 
Operating loss
  
 
(8,984
) 
 
 
(502
) 
 
 
(9,486
) 
Net loss
  
 
(9,657
 )
 
 
 
(502
 )
 
 
 
(10,159
 )
 
Total other comprehensive loss
  
 
(9,688
 )
 
 
 
(502
 )
 
 
 
(10,190
 )
 
Basic and diluted loss per common share
  
 
 (1.18 )
 
 
 
 (0.06 )
 
 
 
 (1.24 )
 
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended June 30, 2022 (unaudited)
  
 
 
Compensation expense for issuance of stock options
  
 
1,617
 
 
 
502
 
 
 
2,119
 
Net loss
  
 
(9,657
 )
 
 
 
(502
 )
 
 
 
(10,159
 )
 
Balance Sheet for September 30, 2022 (unaudited)
  
 
 
Additional
paid-in
capital
  
 
442,066
 
 
 
1,671
 
 
 
443,737
 
Accumulated deficit
  
 
(447,341
 )
 
 
 
(1,671
 )
 
 
 
(449,012
 )
 
Consolidated Statement of Operations and Comprehensive Loss for the three months September 30, 2022 (unaudited)
  
 
 
Research and development expenses
  
 
3,953
 
 
 
112
 
 
 
4,065
 
Selling, general and administrative expenses
  
 
4,519
 
 
 
260
 
 
 
4,779
 
  
 
 
 
 
 
 
 
 
 
 
 
Total operating expenses
  
 
8,472
 
 
 
372
 
 
 
8,844
 
Operating loss
  
 
(7,801
) 
 
 
(372
) 
 
 
(8,173
) 
Net loss
  
 
(8,505
) 
 
 
(372
) 
 
 
(8,877
) 
Total other comprehensive loss
  
 
(8,551
) 
 
 
(372
) 
 
 
(8,923
) 
Basic and diluted loss per common share
  
 
(0.92
) 
 
 
(0.04
) 
 
 
-0.96
 
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)
  
 
 
Compensation expense for issuance of stock options
  
 
1,255
 
 
 
372
 
 
 
1,627
 
Net loss
  
 
(8,505
) 
 
 
(372
) 
 
 
(8,877
) 
Consolidated Statement of Operations and Comprehensive Loss for the six months June 30, 2022 (unaudited)
  
 
 
Research and development expenses
  
 
9,696
 
 
 
391
 
 
 
10,087
 
Selling, general and administrative expenses
  
 
7,791
 
 
 
908
 
 
 
8,699
 
  
 
 
 
 
 
 
 
 
 
 
 
Total operating expenses
  
 
17,487
 
 
 
1,299
 
 
 
18,786
 
Operating loss
  
 
(16,527
) 
 
 
(1,299
) 
 
 
(17,826
) 
Net loss
  
 
(17,860
) 
 
 
(1,299
) 
 
 
(19,159
) 
Total other comprehensive loss
  
 
(17,889
) 
 
 
(1,299
) 
 
 
(19,188
) 
Basic and diluted loss per common share
  
 
(2.18
) 
 
 
(0.16
) 
 
 
(2.34
) 
 
 
 
  
As previously

report
 
 
Adjustment
 
 
As revised
 
Consolidated Statement of Cash Flows for the six months ended June 30, 2022 (unaudited)
  
 
 
Net loss
  
 
(17,860
) 
 
 
(1,299
) 
 
 
(19,159
) 
Stock option compensation expense
  
 
3,091
 
 
 
1,299
 
 
 
4,390
 
Consolidated Statement of Operations and Comprehensive Loss for the nine months September 30, 2022 (unaudited)
  
 
 
Research and development expenses
  
 
13,649
 
 
 
503
 
 
 
14,152
 
Selling, general and administrative expenses
  
 
12,309
 
 
 
1,168
 
 
 
13,477
 
  
 
 
 
 
 
 
 
 
 
 
 
Total operating expenses
  
 
25,958
 
 
 
1,671
 
 
 
27,629
 
Operating loss
  
 
(24,327
) 
 
 
(1,671
) 
 
 
(25,998
) 
Net loss
  
 
(26,365
) 
 
 
(1,671
) 
 
 
(28,036
) 
Total other comprehensive loss
  
 
(26,447
) 
 
 
(1,671
) 
 
 
(28,118
) 
Basic and diluted loss per common share
  
 
(3.09
) 
 
 
(0.20
) 
 
 
(3.29
) 
Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)
  
 
 
Net loss
  
 
(26,365
) 
 
 
(1,671
) 
 
 
(28,036
) 
Stock option compensation expense
  
 
4,345
 
 
 
1,671
 
 
 
6,016